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• Our patient population is extremely heterogenous (various 
primary cancer diagnoses, prior radiation in other regions, 
other treatments such as chemotherapy during or after 
combined treatment, and location and number of 
metastases). Additionally our study was retrospective, 
nonblinded and nonrandomized. 
• These limitations warrant future prospective, randomized 
studies as this treatment modality could yield clinical 
benefit for patients with oligometastatic disease. 
• Ongoing Phase II studies are evaluating the combination 
of anti-pd1 therapy with hypofractionated radiation 
compared to anti-pd1 monotherapy in terms of tumor 
response rates, overall survival, safety profiles, and the 
molecular basis of the synergistic effect between the 
combined modalities5.
• Future studies could utilize quality of life measures6 to 
better capture symptom burden from the patient’s 
perspective.
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Local and Distant Tumor Response Outcomes
Local Response
Complete Response 8 22%
Partial Response 8 22%
Stable Disease 9 24%
Progressive Disease 12 32%
Distant Response
Complete Response 3 8%
Partial Response 5 14%
Stable Disease 3 8%
Progressive Disease 26 70%
• This is an IRB approved retrospective cohort 
study of patients with extra-cranial metastases 
who received treatment with concurrent 
ablative radiotherapy and anti-PD-1 
immunotherapy at LVHN. 
• Patients with stage III and stage IV 
unresectable malignancies 18 years or older 
treated with combined hypofractionated 
ablative radiation therapy and anti-PD-1 from 
1/1/2015 to 12/31/2016 were included.
• Patients who have received chemotherapy 
prior to concurrent treatment, and patients 
who received radiation therapy in same region 
as concurrent treatment location were 
excluded.  
• 29 patients with oligometastatic lesions 
including sarcoma (7%), renal cell carcinoma 
(24%), melanoma (59%), and lung cancer 
(10%), were treated with concurrent radiation 
and anti-PD1 therapy.
• The data was statistically analyzed through 
SPSS to determine outcomes as stated in the 
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Problem Statement
• Radiation therapy has long been used in treating 
unresectable cancer or reducing the risk of local 
recurrence after  surgery1.
• Checkpoint blockade immunotherapy has gained 
increasing attention for treating patients with 
metastatic cancer, specifically in conjunction with 
radiation therapy2. 
• Previous studies of combined therapy have shown 
improved local control of tumor burden with minimal 
adverse events (AEs) (< Grade 3)3.
• Our institution has been treating patients with 
concurrent ablative (stereotactic or hypofractionated) 
radiation therapy (ART) and anti-PD1 immunotherapy 
for various oligometastatic malignancies.
• Long term local and distant treatment response, 
autoimmune adverse events, and survival outcomes in 
our patient cohort are unknown. 
Primary Aim:  Report local and distant treatment response 
in patients with stage IV/unresectable stage III solid tumors
treated with concurrent and sequential hypofractionated 
ablative radiation therapy and anti-PD-1. 
Secondary Aim:  Report overall health outcomes and 
safety profiles of patients treated with this modality. 
Of  37 oligometastatic sites, 68% reached local 
clinical benefit and 30% reached distant benefit:
Median Local Progression-Free Survival 
8.1 months  (95% CI, 5.7 to not reached) 
Median Distant. Progression-Free Survival
8.3 months (95% CI, 5.3-10.7)
Median Overall Survival
19.5 months (95% CI, 10.3 to not reached). 
Grade > 3 toxicity occurred in 8 patients (28%) in 
13 instances including nephritis (17%) 
hypophysitis (8%) colitis (25%) pneumonia (25%) 
and arthritis (25%).
Principal Investigator: Suresh Nair MD
Co-investigators: Samuel G Adediran MD; Jamal Nadeem MD; Alyson McIntosh MD, Hope Kincaid MS; Jennifer Macfarlan MS; 
Bansi Savla MS4, Jason Naziri MD
• In this series, concurrent immunotherapy and 
ablative radiotherapy to oligometastases 
yielded some improvement in tumor control 
and overall survival and moderate rates of 
Grade 3 autoimmune toxicity compared to 
historic controls (monotherapy with 
immunomodulation) and previous studies .
• This treatment is unique as it focuses on 
combining immunotherapy and radiation 
therapy, the success of which heavily relies 
upon the integration of medical oncology, 
radiation oncology, and at the epicenter, the 
patient and their families.4. 
• This process involved multiple SELECT 
competencies, including peer-to-peer 
mentorship, communicating on a 
multidisciplinary platform, and evaluating the 
safety and efficacy of an increasingly utilized 
modality of treating cancer.
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